Director
DIN: 08819218
Revathi Parvatham is currently associated with 2 companies in various capacities such as Individual Promoter and Director. They serve as a Director at NEOVEL PHARMA PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08819218.Revathi Parvatham has previously been associated with 1 company in roles such as Director.Revathi Parvatham is currently involved in 2 different roles. Their most recent position is with BIOVOLT SOLUTIONS PRIVATE LIMITED as a Director. The first company Revathi Parvatham was appointed to as a director was NEOVEL PHARMA PRIVATE LIMITED. Revathi Parvatham is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Revathi Parvatham is currently associated with 2 companies in various capacities such as Individual Promoter and Director. They serve as a Director at NEOVEL PHARMA PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08819218.Revathi Parvatham has previously been associated with 1 company in roles such as Director.Revathi Parvatham is currently involved in 2 different roles. Their most recent position is with BIOVOLT SOLUTIONS PRIVATE LIMITED as a Director. The first company Revathi Parvatham was appointed to as a director was NEOVEL PHARMA PRIVATE LIMITED. Revathi Parvatham is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
2
Female
India
Call +91 81049 46419 and we'll pull the verified contact details for you.
Current Companies (2)
Current LLPs (0)
Past Companies (1)
1y 3m 8 Months Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| NEOVEL PHARMA PRIVATE LIMITED | Individual Promoter | 02-Aug-2020 |
| BIOVOLT SOLUTIONS PRIVATE LIMITED | Director | 18-May-2026 |